Shasun Pharmaceuticals, a global pharmaceutical organization offering world class capabilities and facilities has successfully completed MHRA inspection during the third week of August 2013. The main focus of the inspection was to conduct cGMP audit for the formulation facility.
Shasun Pharmaceuticals manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric coating excipients with a significant presence in some key generics. Shasun has created a strong product portfolio, building on its R&D Expertise, regulatory capabilities and multi scale production capacities. It is one of the largest producers of Ibuprofen worldwide.
